Biotechnology Valuation: An Introductory Guide (The Wiley Finance Series) - Image 1

£57.89

Wiley Biotechnology Valuation: An Introductory Guide (The Wiley Finance Series)

Name: Biotechnology Valuation: An Introductory Guide (The Wiley Finance Series)
Brand: Wiley
Price: 57.89 GBP
Availability: InStock

Stocks & Shares

About as cheap as it gets. The only time it was cheaper was 2 months ago.

£58 today · all-time low £55 (Apr 2026) · usually £58

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 74 days • 74 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 74 days • 3 price levels

Days at Price

Current Price

Price Analysis

Most common price: £58 (31 days, 41.9%)

Price range: £56 - £59

Price levels: 3 different prices over 74 days

Description

The first book to provide a simple and practical means of valuing biotech companies The book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips It examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the US Looks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate them Praise for Biotechnology Valuation "Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns. Keegan's book, punctuated with his personal experience and opinions, is a good place to start." ―Chris Blackwell, Chief Executive, Vectura Group plc "A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians." ―Steve Winokur, Managing Director, CanaccordAdams "A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value." ―Dr L.M. Allan, Director, Bioscience Enterprise Programme, University of Cambridge "A fabulous approach to a difficult topic." ―Deirdre Y. Gillespie, MD, President & CEO, La Jolla Pharmaceutical Company

Product Specifications

Brand: Wiley
Format: hardcover
ASIN: 0470511788
Category: Books > Subjects > Business, Finance & Law > Professional Finance > Investments & Securities > Stocks & Shares
Domain: Amazon UK
Release Date: 21 November 2008
Listed Since: 08 May 2007

Barcode

No barcode data available

Wiley Biotechnology Valuation: An Introductory Guide (The Wiley Finance Series)

About as cheap as it gets. The only time it was cheaper was 2 months ago.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Novel Therapeutics from Modern Biotechnology: From Laboratory to Human Testing: 137 (Handbook of Experimental Pharmacology, 137)

Molecular Biotechnology: Principles and Applications of Recombinant DNA (ASM Books)

The Pharmagellan Guide to Biotech Forecasting and Valuation

Innovation and Entrepreneurship in Biotechnology, An International Perspective: Concepts, Theories and Cases

Biotechnology Entrepreneurship: Leading, Managing and Commercializing Innovative Technologies

Springer - The Business of Bioscience Book

Biotechnology, Patents and Human Rights in Europe: Innovations Concerning the Human Body

Innovation and Entrepreneurship in Biotechnology, An International Perspective: Concepts, Theories and Cases

Springer - The Business of Bioscience Book

Introduction to Biotech Entrepreneurship: From Idea to Business: A European Perspective

Wiley Biotech Industry - Global Economic and Financing Overview

Innovation and Commercialisation in the Biopharmaceutical Industry: Creating and Capturing Value

Plunkett's Biotech, Pharmaceuticals & Genetics Industry Almanac 2024: Biotech, Pharmaceuticals & Genetics Industry Market Research, Statistics, Trends and Leading Companies

Pharmaceutical Biotechnology: Drug Discovery and Clinical Applications

In vitro Environmental Toxicology - Concepts, Application and Assessment: 157 (Advances in Biochemical Engineering/Biotechnology, 157)

Biotechnological Inventions and Patentability of Life: The US and European Experience (New Directions in Patent Law series)

Biotechnology in India II: 85 (Advances in Biochemical Engineering/Biotechnology)

Comprehensive Biotechnology, 2nd edition

Biotechnology: A Comprehensive Training Guide for the Biotechnology Industry

The International Law of Biotechnology: Human Rights, Trade, Patents, Health and the Environment: Second Edition (Principles of International Law series)

Biotechnology and its Applications: Using Cells to Change the World

Biotechnology and Software Patent Law: A Comparative Review of New Developments (New Directions in Patent Law series)

Biotechnology Annual Review (Volume 2)

Valuations of Early-Stage Companies and Disruptive Technologies: How to Value Life Science, Cybersecurity and ICT Start-ups, and their Technologies